 EXTON, Pa., May 11, 2021 GLOBE NEWSWIRE -- Recro Pharma, Inc. Recro; NASD:REPH, a contract development and manufacturing organization CDMO dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares to be sold in the public offering will be sold by Recro. Recro is expected to grant the underwriters a 30-day option to purchase up to an additional 15 of the shares of common stock being offered at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 